INTERCEPT PHARMACEUTICALS, INC. Insider Trading for April 2015
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in INTERCEPT PHARMACEUTICALS, INC..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in INTERCEPT PHARMACEUTICALS, INC. for April 2015.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 22 2015 | ICPT | INTERCEPT PHARMACE ... | WILLIAMS NICOLE | Director | Option Exercise | M | 9.82 | 974 | 9,567 | 3,029 | |
| Apr 22 2015 | ICPT | INTERCEPT PHARMACE ... | WILLIAMS NICOLE | Director | Sell | S | 278.50 | 974 | 271,259 | 962 | 1.9 K to 962 (-50.31 %) |
| Apr 22 2015 | ICPT | INTERCEPT PHARMACE ... | WILLIAMS NICOLE | Director | Buy | M | 9.82 | 974 | 9,567 | 1,936 | 962 to 1.9 K (+101.25 %) |
| Apr 14 2015 | ICPT | INTERCEPT PHARMACE ... | VEITINGER KLAUS R DR | Director | Option Exercise | M | 21.50 | 391 | 8,407 | 8,754 | |
| Apr 14 2015 | ICPT | INTERCEPT PHARMACE ... | VEITINGER KLAUS R DR | Director | Sell | S | 272.10 | 391 | 106,391 | 2,166 | 2.6 K to 2.2 K (-15.29 %) |
| Apr 14 2015 | ICPT | INTERCEPT PHARMACE ... | VEITINGER KLAUS R DR | Director | Buy | M | 21.50 | 391 | 8,407 | 2,557 | 2.2 K to 2.6 K (+18.05 %) |
| Apr 08 2015 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Option Exercise | M | 8.67 | 4,000 | 34,667 | 4,000 | |
| Apr 08 2015 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Sell | S | 271.64 | 2,000 | 543,280 | 10,060 | 12.1 K to 10.1 K (-16.58 %) |
| Apr 08 2015 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Sell | S | 269.11 | 1,000 | 269,110 | 12,060 | 13.1 K to 12.1 K (-7.66 %) |
| Apr 08 2015 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Sell | S | 266.18 | 1,000 | 266,180 | 13,060 | 14.1 K to 13.1 K (-7.11 %) |
| Apr 08 2015 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Buy | M | 8.67 | 4,000 | 34,667 | 14,060 | 10.1 K to 14.1 K (+39.76 %) |
| Apr 03 2015 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Option Exercise | M | 8.67 | 2,131 | 18,469 | 33,294 | |
| Apr 03 2015 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Option Exercise | M | 10.40 | 203 | 2,111 | 0 | |
| Apr 03 2015 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Option Exercise | M | 0.00 | 1,622 | 0 | 4,868 | |
| Apr 03 2015 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 277.70 | 843 | 234,102 | 19,293 | 20.1 K to 19.3 K (-4.19 %) |
| Apr 03 2015 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 281.15 | 1,000 | 281,150 | 20,136 | 21.1 K to 20.1 K (-4.73 %) |
| Apr 03 2015 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 272.69 | 282 | 76,897 | 21,136 | 21.4 K to 21.1 K (-1.32 %) |
| Apr 03 2015 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 269.83 | 1,334 | 359,953 | 21,418 | 22.8 K to 21.4 K (-5.86 %) |
| Apr 03 2015 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Buy | M | 8.67 | 2,131 | 18,469 | 22,752 | 20.6 K to 22.8 K (+10.33 %) |
| Apr 03 2015 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Buy | M | 10.40 | 203 | 2,111 | 20,621 | 20.4 K to 20.6 K (+0.99 %) |
| Apr 03 2015 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Buy | M | 0.00 | 1,622 | 0 | 20,418 | 18.8 K to 20.4 K (+8.63 %) |
| Apr 03 2015 | ICPT | INTERCEPT PHARMACE ... | Duncan Barbara Gayle | Chief Financial Off ... | Option Exercise | M | 0.00 | 1,298 | 0 | 3,894 | |
| Apr 03 2015 | ICPT | INTERCEPT PHARMACE ... | Duncan Barbara Gayle | Chief Financial Off ... | Sell | S | 277.70 | 39 | 10,830 | 17,523 | 17.6 K to 17.5 K (-0.22 %) |
| Apr 03 2015 | ICPT | INTERCEPT PHARMACE ... | Duncan Barbara Gayle | Chief Financial Off ... | Buy | M | 0.00 | 1,298 | 0 | 17,562 | 16.3 K to 17.6 K (+7.98 %) |
| Apr 03 2015 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Option Exercise | M | 0.00 | 649 | 0 | 1,947 | |
| Apr 03 2015 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Buy | M | 0.00 | 649 | 0 | 10,060 | 9.4 K to 10.1 K (+6.90 %) |
| Apr 03 2015 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Option Exercise | M | 0.00 | 4,868 | 0 | 14,603 | |
| Apr 03 2015 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Sell | S | 277.70 | 157 | 43,599 | 495,743 | 495.9 K to 495.7 K (-0.03 %) |
| Apr 03 2015 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Buy | M | 0.00 | 4,868 | 0 | 495,900 | 491 K to 495.9 K (+0.99 %) |
| Apr 01 2015 | ICPT | INTERCEPT PHARMACE ... | Duncan Barbara Gayle | Chief Financial Off ... | Sell | S | 293.34 | 300 | 88,001 | 16,264 | 16.6 K to 16.3 K (-1.81 %) |
| Apr 01 2015 | ICPT | INTERCEPT PHARMACE ... | Duncan Barbara Gayle | Chief Financial Off ... | Sell | S | 292.16 | 100 | 29,216 | 16,564 | 16.7 K to 16.6 K (-0.60 %) |
| Apr 01 2015 | ICPT | INTERCEPT PHARMACE ... | Duncan Barbara Gayle | Chief Financial Off ... | Sell | S | 291.00 | 100 | 29,100 | 16,664 | 16.8 K to 16.7 K (-0.60 %) |
| Apr 01 2015 | ICPT | INTERCEPT PHARMACE ... | Duncan Barbara Gayle | Chief Financial Off ... | Sell | S | 289.00 | 100 | 28,900 | 16,764 | 16.9 K to 16.8 K (-0.59 %) |
| Apr 01 2015 | ICPT | INTERCEPT PHARMACE ... | Duncan Barbara Gayle | Chief Financial Off ... | Sell | S | 288.00 | 100 | 28,800 | 16,864 | 17 K to 16.9 K (-0.59 %) |
| Apr 01 2015 | ICPT | INTERCEPT PHARMACE ... | Duncan Barbara Gayle | Chief Financial Off ... | Sell | S | 287.00 | 100 | 28,700 | 16,964 | 17.1 K to 17 K (-0.59 %) |
| Apr 01 2015 | ICPT | INTERCEPT PHARMACE ... | Duncan Barbara Gayle | Chief Financial Off ... | Sell | S | 286.00 | 100 | 28,600 | 17,064 | 17.2 K to 17.1 K (-0.58 %) |
| Apr 01 2015 | ICPT | INTERCEPT PHARMACE ... | Duncan Barbara Gayle | Chief Financial Off ... | Sell | S | 285.00 | 100 | 28,500 | 17,164 | 17.3 K to 17.2 K (-0.58 %) |